Steven Holtzman joined Decibel as president and chief executive officer in 2016. Steve brings more than 30 years of strategic, operational and leadership experience in the biotechnology industry. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc., where he created and led the program leadership and management group through eight new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions.

Prior to Biogen, Steve served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in large scale genetics and genomics, and was a founder, member of the board and the executive vice president of DNX Corporation, the first transgenic animal company. Steve is a member of the boards of directors of Visterra, Humatics, The Sync Project and Molecular Partners. In the not-for-profit arena, Steve is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission.

Steve received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.

Michael Su joined Decibel as chief scientific officer in August 2016. Prior to Decibel, Michael served as co-founder and senior vice president of research and development at Agios Pharmaceuticals. Michael has more than 25 years of organization, project management and scientific experience in the biotechnology industry. During his time at Agios, he led the team responsible for identifying oncogenic causes for the company’s lead mutant isocitrate dehydrogenase programs and led the discovery of the resulting drug candidates, which are currently in late-stage clinical development. In addition, he chaired the Agios-Celgene joint research collaboration from 2010 to 2013 and led drug discovery in the rare genetic diseases franchise. From 2004 to 2006, he served as general director and vice president of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior to that, he spent 14 years in a number of roles, concluding his tenure as program executive and vice president of the Novartis kinase collaboration for Vertex Pharmaceuticals. Michael completed his Ph.D. in biochemistry from Duke University followed by accepting the Helen Hay Whitney fellowship in biochemistry and molecular biology at Harvard University. He has been published over 50 times with more than 20 issued and pending patents.

Leslie Shinobu joined Decibel in September 2015 serves as chief of translational research. Prior to Decibel, Leslie spent the last two years working behind the scenes to support Third Rock Ventures’ new companies. She couples a passion for making life better for patients with this first-hand experience shaping early company formation, and more than 30 years of translational expertise acquired in both academic and industry settings.

Leslie’s industry experience spans 12 years across biotech and big pharma working on late-stage programs for the multiple sclerosis drugs Avonex, Tysabri, Cladribine (Biogen Idec, Merck Serono) and many early development programs (Biogen Idec, GlaxoSmithKline, Takeda Pharmaceuticals) that have successfully transitioned into the clinic. Her most recent position prior to joining Third Rock was vice president, head of the CNS drug development unit within Takeda.

Leslie completed her Ph.D. in inorganic chemistry at The Center in Environmental Toxicology at Vanderbilt University. Her subsequent medical training at Vanderbilt was followed by residency and chief residency on the neurology service at Massachusetts General Hospital (MGH). She remained on faculty at MGH for over 20 years conducting bench to bedside research and designing clinical programs relevant to movement disorders and amyotrophic lateral sclerosis.

Leslie previously served on the editorial board of the American Society of Experimental Therapeutics and the scientific advisory board of what is now NBIAcure, and worked pro bono for a number of foundations and institutes, including the Huntington Study Group, Common Mind Consortium, Alzheimer Disease Neuroimaging Initiative, the innovation hub MaRS Discovery District, and the Department of Defense Hearing Center of Excellence led Pharmaceutical Interventions for Hearing Loss.

John Keilty joins Decibel from Third Rock Ventures where he served as the general manager of platform operations, responsible for the development and implementation of technology roadmaps for companies across the portfolio. Prior to this role, John was the vice president of information technology and informatics at Infinity Pharmaceuticals where he owned information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. Before joining Infinity in 2002, John was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, with broad ownership for the creation, management, implementation and transfer of many of the company’s core genomic technologies. Before Millennium, John worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing.

John received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.

Paula Cobb joined Decibel in September 2016 as executive vice president of corporate development. Prior to Decibel, Paula served as senior vice president of the rare disease group at Biogen. With more than 13 years of experience in the biotechnology industry, Paula has led teams to three new drug approvals and played key roles on four product launches. At Biogen, Paula served in various senior and global roles. As senior vice president of the rare disease group, she was responsible for the company’s marketed hemophilia assets and Phase 3 programs in spinal muscular atrophy and neuropathic pain. Prior to this role, Paula managed the multiple sclerosis franchise, led new product commercialization for early pipeline programs, served as chief of staff to the CEO, and held various operational management roles with Biogen in Europe. Before Biogen, Paula worked for various consulting groups in the Boston area. Paula graduated cum laude from Amherst College with a Bachelor of Arts degree in political science and English. She also received an MBA from Harvard University Graduate School of Business Administration.
John Lee joined Decibel in September 2016 as senior vice president of pharmaceutical development, and brings over 20 years of R&D, operational and leadership experience in the biotechnology industry. Prior to Decibel, he served as senior vice president of pharmaceutical development at Infinity Pharmaceuticals. Over the course of his 15 years at Infinity, John held roles of increasing responsibility and leadership. Most recently, he was responsible for chemistry, manufacturing and control (CMC), analytical sciences, formulation sciences, and clinical supply and distribution for the company’s drug candidates across all phases of global clinical development, as well as co-chair of Infinity’s operational leadership team. Prior to Infinity, John was a new product manager at Corning Life Science where he was responsible for developing new life science products from Corning research and technologies. Before Corning, John was an early member of Millennium Pharmaceuticals and played a key role in the successful positional cloning of the mouse obesity gene tubby, before taking on the role of project lead for an ovarian cancer diagnostic program. Prior to Millennium, John worked in the developmental chronobiology lab of Steven Reppert at Massachusetts General Hospital, where he focused on cloning G-protein coupled receptors and circadian biology. John received his bachelor of science in materials science and engineering from the Massachusetts Institute of Technology.
Pete Castrichini joined Decibel as vice president, people, community, and culture in September 2016. Prior to Decibel, Pete served as senior vice president of human resources at Interactive Data Corporation, a critical supplier of real-time financial investment data to major global financial institutions. Pete has more than 30 years of diverse experience across dynamic businesses building, managing and leading the human resource function. During his seven years at Interactive Data, Pete developed and implemented a global on-boarding program, worked with the board of directors to develop the company’s reward strategy and implement new equity and bonus plans, and was instrumental in the human resource integration for multiple acquisitions. Prior to Interactive Data, Pete served two years as vice president of global compensation, benefits and human resource operations at Monster Worldwide Inc. Before Monster, he spent nine years at Millennium Pharmaceuticals Inc., serving as senior director of human resources with responsibility for staffing, total rewards, and human resource operations, and ten years in roles of escalating responsibility at Digital Equipment Corporation. Pete graduated for the University of Vermont with a bachelor of arts in economics and became a certified compensation professional via World-At-Work.

Ronald Vigliotta joined Decibel as senior director, finance in November 2016 and has more than 20 years of diverse accounting and finance experience, including in both public and private biotechnology companies.  Prior to Decibel, Ron served as senior director, finance at Warp Drive Bio for three years, where he led both the accounting and finance functions.  Prior to Warp Drive Bio, Ron worked at Infinity Pharmaceuticals for seven years where he held various roles of increasing responsibility including Controller. Before Infinity, he spent five years at Hilb, Rogal and Hobbs, an insurance brokerage company, serving as agency controller. He also worked at Ernst & Young  for six years in the assurance and advisory business group servicing clients in multiple industries. Ron graduated from Fairfield University with a bachelor of science in accounting and finance and is a certified public accountant.